Monitoring and Modifying Treatment in PAH

Suggested Baseline and Serial Assessment of Patients With PAH

Why Modify Targeted PAH Therapy?

Determinants of Prognosis in PAH

Case Study 1: A 47-Year-Old Man With Heritable PAH (HPAH)

Options to Current Regimen of Inhaled Prostanoid

Recommendations for WHO FC II PAH Patients

Repeat RHC?

PAH: A Heterogeneous Group of Clinical Entities

Importance of Communication Between Specialist and Primary Care Physician

Case Study 2: A 51-Year-Old Woman With Scleroderma-Associated PAH (SSc PAH)

Six Months Later…

Revisiting the Initial Therapy Choice

Pharmacologic Agents for PAH 3 Pathways

The Rationale for Combination Therapy

AMBITION Study Design

AMBITION Study Primary Endpoint* Results

Revisiting Therapeutic Decision Made at First Follow-Up Visit

French Registry Low-Risk Criteria

COMPERA Registry Risk Stratification

Summary of 3 European Studies

Case Review and Current Status

GRIPHON Study Design

GRIPHON Titration and Dosing

GRIPHON Treatment Effect by Subgroup

Worrisome Features of This Case

Take-Home Points

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)